HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	10/14/2002 5:14:48 AM
From: nigel bates	of 1022

Comments of potential interest from the CRXL results statement - The market continues to be faced with a shortage in antibody production capacity, a field in which Crucell actively markets its PER.C6(TM) production platform. The company also continues to develop alliances with contract manufacturing organizations to increase capacity and to make PER.C6(TM) derived products widely available. Crucell actively promotes its PER.C6(TM) production cell line for the production of new viral vaccines. Although sales of existing antibodies are accelerating, the market faced a number of setbacks in the development and approval of new products world-wide. Due to limited early licensing opportunities currently available, Crucell is focusing on further in-house development of its pre-clinical product leads. The company is expected to reach profitability once products are brought to market by licensees using Crucell's technology... Message 18109510

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next